Med-Tech

11 December 2018

MedaPhor – Parkwalk investment

By |December 11th, 2018|

We are delighted to announce that the Parkwalk Opportunities Fund has  participated in the recent financing round of Medaphor Group plc, the Cardiff University Spin-out and global provider of advanced ultrasound training simulators and ultrasound clinical support for medical professionals.

20 October 2018

DefiniGEN – Parkwalk closes follow on investment

By |October 20th, 2018|

Parkwalk closes DefiniGen investment.

DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human cells to the drug discovery sector for use in lead optimisation and toxicity programmes.

The Company’s proprietary production platform OptiDIFF robustly generates human cell types including using hIPSC human […]

27 September 2018

Healthera – UCEF V investment

By |September 27th, 2018|

We are delighted to announce that the University of Cambridge Enterprise Fund V has invested in a £3m Series A financing round into Healthera, a provider of next-generation, pharmacy-integrated personal health management solutions.

Healthera connects patients to a platform of hundreds of pharmacies and NHS GPs, allowing them to order and track prescriptions, access clinical […]

3 April 2018

Micrima – University of Bristol Enterprise Fund II investment

By |April 3rd, 2018|

We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Micrima.

Micrima is a Bristol based diagnostic imaging company, developing a new Breast Imaging System (MARIA) aimed at radically improving breast cancer detection and survival rates through the provision of much safer, more frequent, more comfortable and […]

28 March 2018

Oxford Endovascular – Parkwalk and UOIF IV investment

By |March 28th, 2018|

We have recently closed an investment in Oxford Endovascular for the Parkwalk Opportunities EIS Fund and the University of Oxford Innovation Fund IV.

Oxford Endovascular have developed Oxiflow, a novel, next generation ‘flow-diverter’ that diverts blood flow away from intracranial aneurysms at risk of rupture. The device is a metallic mesh tube, laser cut from Nitinol […]

Brainomix – Parkwalk closes follow-on investment

By |March 7th, 2018|

We have recently closed an investment in Brainomix for the Parkwalk Opportunities EIS Fund and the University of Oxford Innovation Fund IV.

Brainomix, the medical imaging company using artificial intelligence (AI) for the fast diagnosis and treatment of stroke victims, has closed a £7m ($9.8m) funding roundt to bring its software to the global healthcare market.

Parkwalk lead […]

20 February 2018

OxSyBio – Parkwalk closes Investment

By |February 20th, 2018|

We are delighted to announce that Parkwalk has participated in the funding of OxSyBio, which is seeking to commercialise IP generated by Professor Hagan Bayley at the University of Oxford.

The company has the unique ability to 3D print materials that have function derived from biology, but which are not living. The company is also able to print […]

16 January 2018

Dynamic Vision Systems – Parkwalk closes investment

By |January 16th, 2018|

We are pleased to announce that we have closed an investment into the University of Manchester spinout Dynamic Vision Systems (DVS) for the Parkwalk Opportunities Fund. The company is built on collaborative efforts at the University of Manchester and the University of Leeds in the field of smart contact lenses.

The DVS technology arose from […]

13 October 2017

MedaPhor – Parkwalk investment

By |October 13th, 2017|

We are delighted to announce that the Parkwalk Opportunities Fund has  participated in the recent financing round of Medaphor Group plc, the Cardiff University Spin-out and global provider of advanced ultrasound training simulators for medical professionals.

3 July 2017

Creavo Medical Technologies – Parkwalk closes investment

By |July 3rd, 2017|

We are pleased to announce that the Parkwalk Opportunities Fund has made an investment in Creavo Medical Technologies, a University of Leeds Spin-out company, as part of a £13.4 million fundraising.

The round was oversubscribed, exceeded Creavo’s funding target and was strongly supported by existing shareholders including IP Group plc, the University of Leeds, and new, private and […]

9 May 2017

Brainomix joins forces with Boehringer Ingelheim to help save stroke victims

By |May 9th, 2017|

Oxford – An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.

The Brainomix team has pioneered the rapid digital analysis of scans of patients admitted to hospital with stroke. […]

28 February 2017

Sphere Medical – Results for the year ended 31 December 2016

By |February 28th, 2017|

Sphere Medical Holding plc (AIM: SPHR.L), an innovative point-of-care monitoring and diagnostic devices company, announces its results for the year ended 31 December 2016.
 
Business highlights for 2016 and post year-end
 
·        Successful commercial launch of Proxima 4 in mid-December 2016 in Europe with encouraging early market reaction
·        First sales of Proxima 4 achieved
·        Over 20 […]

14 December 2016

Brainomix – International Journal of Stroke Publication

By |December 14th, 2016|

Oxford – A new clinical study was conducted by Anglia Ruskin Clinical Trials Unit reporting the performance of e-ASPECTS. In this multi-centre study, non-contrast enhanced computed tomography (NCCT) images from ischemic stroke patients were evaluated by e-ASPECTS and 3 independent neuroradiologists and compared to ground truth ASPECTS scores determined by a core imaging lab. […]

1 September 2016

Healthera – University of Cambridge Enterprise Fund III investment

By |September 1st, 2016|

We are delighted to announce that the University of Cambridge Enterprise Fund III has invested in Healthera Ltd, a provider of next-generation, pharmacy-integrated personal health management solutions, has secured seed investment from the University of Cambridge, the University of Cambridge Enterprise Fund III, FT Capital and high net worth individuals. The specific amounts are undisclosed.

This […]

31 August 2016

Brainomix – Parkwalk closes follow-on investment

By |August 31st, 2016|

We have recently closed an investment in Brainomix for the Parkwalk UK Tech Fund VII and the Opportunities Fund.

Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses for their patients.

Brainomix’s ground-breaking technology, e-ASPECTS is a clinical decision support tool that automatically implements the Alberta […]

Micrima – University of Bristol Enterprise Fund I investment

By |August 10th, 2016|

We are delighted to announce that the University of Bristol Enterprise Fund I, managed by Parkwalk, has invested in Micrima.

The company intends to develop and commercialise a new Breast Imaging System (MARIA) aimed at radically improving breast cancer detection and survival rates through the provision of much safer, more frequent, more comfortable and less expensive […]

21 April 2016

DefiniGEN – Parkwalk closes follow on investment

By |April 21st, 2016|

Parkwalk closes DefiniGen investment for the University of Cambridge Enterprise Fund IV and Parkwalk Funds

DefiniGEN, a spin-out from the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital, have created a stem cell technology to provide human cells to the drug discovery sector for use in lead optimisation and toxicity programmes.

The Company’s proprietary production […]

21 December 2015

Oxford Endovascular – Parkwalk closes University of Oxford Isis Fund investment

By |December 21st, 2015|

We are delighted to announce that the University of Oxford Isis Fund II has completed an investment in Oxford Endovascular Limited, a company developing sophisticated mesh tubes to treat patients suffering from brain aneurysms. Parkwalk invested in a £2m round alongside the new Oxford Sciences Innovation plc.

The Oxford technology uses a special laser-cut metal alloy which has a […]

11 August 2015

Brainomix – receives Biomedical Catalyst funding to develop clinical decision-making software for stroke patients

By |August 11th, 2015|

Oxford, UK: Brainomix Limited, a developer of automated medical imaging software for neurological and cerebrovascular disorders, has been awarded £633,553 by the Biomedical Catalyst, a joint programme run by the Medical Research Council (MRC) and Innovate UK. The funding is for two years and will support the development and validation of clinical decision-making support […]

26 June 2015

Parkwalk closes Orthox investment

By |June 26th, 2015|

We are pleased to announce that Parkwalk VI, the Opportunities EIS Fund and the University of Oxford Isis Fund II have made an investment in Orthox,  a tissue regenerative orthopaedic implant company with technology spun out of Oxford University.

Orthox is a medical device company founded in 2008 to exploit FibroFix, a novel silk-based biomaterial platform, for the […]